[
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
    "summary": "Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES",
    "url": "https://finance.yahoo.com/news/akebia-therapeutics-reports-third-quarter-120000816.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a8740fb4-a534-3b81-aec8-7d8c17f9a699",
      "content": {
        "id": "a8740fb4-a534-3b81-aec8-7d8c17f9a699",
        "contentType": "STORY",
        "title": "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
        "description": "",
        "summary": "Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1",
          "originalWidth": 4321,
          "originalHeight": 1761,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RlzKdoLm0SQudsf4h9YvVg--~B/aD0xNzYxO3c9NDMyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1.cf.webp",
              "width": 4321,
              "height": 1761,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a5_CzxY8Vcp3JCQO3Btxnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/akebia-therapeutics-reports-third-quarter-120000816.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/akebia-therapeutics-reports-third-quarter-120000816.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AKBA"
            },
            {
              "symbol": "DVA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]